利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1442 条记录 (耗时 0.026 秒)

    COMPOSITIONS FOR LABELING NERVES AND METHODS OF USE
    21.
    发明公开
    COMPOSITIONS FOR LABELING NERVES AND METHODS OF USE 审中-公开
    组合物用于标记神经及使用方法

    公开(公告)号：EP2611822A4

    公开(公告)日：2014-04-16

    申请号：EP11822751

    申请日：2011-09-02

    申请人： AVELAS BIOSCIENCES INC

    发明人： GONZALEZ JESUS ,  LIU JUNJIE

    IPC分类号： C07K7/08 ,  A61K38/08 ,  A61K38/10 ,  A61K47/48 ,  A61K49/14 ,  C07K5/00 ,  C07K7/06

    CPC分类号： C07K7/06 ,  A61K49/0056 ,  G09F13/04 ,  G09F13/18 ,  G09F13/22 ,  G09F13/44 ,  G09F2013/1863

    摘要： An illuminated signage system having a printed surface and at least one electroluminescent element embedded within the printed surface and a substrate layer or coupled between the printed surface and the substrate layer, and a rigid backing substrate. Also, an illuminated signage system having a non-opaque material with an etched portion that diffuses light from a light source adjacent to the non-opaque material and a printed layer having indicia visible through the non-opaque material. Also, a method of forming an illuminated signage system, the method including providing a printed surface, coupling the printed surface to a substrate layer, and embedding an electroluminescent element through the printed surface and into at least the substrate layer.

    摘要翻译： 具有印刷表面和至少一个电致发光元件嵌入所述印刷表面和层基板内或耦合在印刷表面和基片层，和刚性背衬基板之间的照明标牌系统。 因此，要照亮的标牌系统具有在蚀刻部分从光源邻近所述非不透明材料，并通过非不透明材料具有标记可见的印刷层做漫射光的非不透明材料。 所以，在形成于照明标志系统的方法，该方法包括：提供印刷表面，所述印刷表面耦合到层的基材，和通过印刷表面并进入至少基板层电致发光元件的嵌入。

    Translocation and mutant ROS kinase in human non-small cell lung carcinoma
    25.
    发明公开
    Translocation and mutant ROS kinase in human non-small cell lung carcinoma 有权
    转录与突变 - ROS-激酶酶活性调节因子

    公开(公告)号：EP2671954A3

    公开(公告)日：2014-02-12

    申请号：EP13176525.7

    申请日：2007-01-19

    申请人： Cell Signaling Technology, Inc.

    发明人： Guo, Ailan ,  Possemato, Anthony

    IPC分类号： C12Q1/68 ,  G01N33/50 ,  C12N15/00 ,  C07K5/00 ,  C07H21/02

    CPC分类号： C07K14/82 ,  A61K31/7088 ,  A61K39/00 ,  C12N15/1135 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N33/574

    摘要： In accordance with the invention, a novel gene translocation, (4p15, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of Sodium-dependent Phosphate Transporter Isoform NaPi-3b protein (SLC34A2) with Proto- oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The SLC34A2-ROS fusion protein is anticipated to drive the proliferation and survival of a subgroup of NSCLC tumors. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of the new fusion protein enables new methods for determining the presence of these mutant ROS kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.

    摘要翻译： 根据本发明，在人非小细胞肺癌（NSCLC）中的新型基因易位（4p15,6q22），其导致结合部分钠依赖性磷酸转运蛋白同种型NaPi-3b蛋白（SLC34A2）的融合蛋白， 与原癌基因酪氨酸蛋白激酶ROS前体（ROS）激酶现已被鉴定。 预期SLC34A2-ROS融合蛋白将驱动NSCLC肿瘤亚组的增殖和存活。 因此，本发明部分地提供分离的多核苷酸和编码所公开的突变型ROS激酶多肽的载体，用于检测其的探针，分离的突变多肽，重组多肽和用于检测融合和截短的多肽的试剂。 所公开的新融合蛋白的鉴定使得能够确定生物样品中这些突变型ROS激酶多肽的存在的新方法，用于筛选抑制蛋白质的化合物的方法，以及抑制以突变型多核苷酸为特征的癌症进展的方法 或多肽，其也由本发明提供。